Capital Impact Advisors LLC Has $2.05 Million Stake in Supernus Pharmaceuticals Inc (SUPN)

Capital Impact Advisors LLC lifted its stake in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 8.6% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 41,004 shares of the specialty pharmaceutical company’s stock after buying an additional 3,239 shares during the period. Capital Impact Advisors LLC’s holdings in Supernus Pharmaceuticals were worth $2,048,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Glenmede Trust Co. NA increased its holdings in shares of Supernus Pharmaceuticals by 3.2% in the second quarter. Glenmede Trust Co. NA now owns 652,806 shares of the specialty pharmaceutical company’s stock worth $39,070,000 after buying an additional 20,012 shares during the period. Cynosure Advisors LLC increased its holdings in shares of Supernus Pharmaceuticals by 55.0% in the second quarter. Cynosure Advisors LLC now owns 8,260 shares of the specialty pharmaceutical company’s stock worth $494,000 after buying an additional 2,930 shares during the period. SevenBridge Financial Group LLC purchased a new position in shares of Supernus Pharmaceuticals in the second quarter worth about $113,000. OppenheimerFunds Inc. increased its holdings in shares of Supernus Pharmaceuticals by 12.2% in the second quarter. OppenheimerFunds Inc. now owns 305,402 shares of the specialty pharmaceutical company’s stock worth $18,278,000 after buying an additional 33,092 shares during the period. Finally, Creative Planning increased its holdings in shares of Supernus Pharmaceuticals by 27.1% in the second quarter. Creative Planning now owns 20,719 shares of the specialty pharmaceutical company’s stock worth $1,240,000 after buying an additional 4,415 shares during the period. Hedge funds and other institutional investors own 97.45% of the company’s stock.

Several research analysts have recently commented on SUPN shares. Piper Jaffray Companies set a $47.00 price objective on Supernus Pharmaceuticals and gave the stock a “hold” rating in a report on Sunday, July 8th. Zacks Investment Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, August 1st. Mizuho started coverage on Supernus Pharmaceuticals in a report on Monday, September 17th. They issued a “buy” rating and a $61.00 price objective on the stock. Cantor Fitzgerald set a $56.00 price objective on Supernus Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 8th. Finally, BidaskClub upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, June 22nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $54.67.

Shares of NASDAQ:SUPN opened at $47.91 on Friday. Supernus Pharmaceuticals Inc has a 1 year low of $33.30 and a 1 year high of $61.25. The stock has a market cap of $2.54 billion, a P/E ratio of 27.14 and a beta of 0.79. The company has a current ratio of 2.74, a quick ratio of 2.54 and a debt-to-equity ratio of 0.82.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $0.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.14. Supernus Pharmaceuticals had a return on equity of 30.57% and a net margin of 24.17%. The company had revenue of $99.54 million for the quarter, compared to the consensus estimate of $101.01 million. On average, analysts expect that Supernus Pharmaceuticals Inc will post 1.93 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Read More: Determine Your Level of Risk Tolerance

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply